HIV resistance to reverse transcriptase inhibitors. [Biochem Pharmacol. 1994]

SearchDatabase nameforSearch term

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

1: Biochem Pharmacol. 1994 Jan 20;47(2):155-69. Links

HIV resistance to reverse transcriptase inhibitors.

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.

PMID: 7508227 [PubMed - indexed for MEDLINE]

Fluorescent HIV-1 Dimerization Initiation Site: design, properties, and use for ligand discovery.
Tam VK, Kwong D, Tor Y. J Am Chem Soc. 2007 Mar 21; 129(11):3257-66. Epub 2007 Feb 24.

[J Am Chem Soc. 2007]
Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.
Asif G, Hurwitz SJ, Gumina G, Chu CK, McClure HM, Schinazi RF. Antimicrob Agents Chemother. 2005 Feb; 49(2):560-4.

[Antimicrob Agents Chemother. 2005]
Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity.
Dutschman GE, Grill SP, Gullen EA, Haraguchi K, Takeda S, Tanaka H, Baba M, Cheng YC. Antimicrob Agents Chemother. 2004 May; 48(5):1640-6.

[Antimicrob Agents Chemother. 2004]
» See all...

Nevirapine (Viramune® )
Nevirapine is used in combination with other medications to treat human immunodeficiency virus (HIV) infection in patients with or without acquired immunodeficiency syndrome (AIDS). Nevirapine is in a class of medication...
Source: AHFS Consumer Medication Information

Your browsing activity is empty.

Activity recording is turned off.

Display Show